KLRS
Kalaris Therapeutics, Inc.
$4.71
-0.12 (-2.48%)
At close · Jul 8
Market Cap
$112.06M
Shares
23,792,278
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$165K
FY2020
Net Income
-$43.44M
+26.1%
FY2025
Operating Margin
-43217.58%
FY2020
Diluted EPS
-$2.85
+75.7%
FY2025
Operating Cash Flow
-$38.37M
+43.3%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|---|
| — | — | — | — | — | — | $165K | |
| $32.3M | $30.75M | $12.34M | $133.07M | $118.87M | $120.74M | $49.66M | |
| $15.34M | $15.4M | $42.92M | $48.26M | $52.33M | $49.08M | $21.65M | |
| — | — | $398K | $398K | $723K | $189K | $73K | |
| — | — | $10.19M | — | — | — | — | |
| $47.63M | $46.15M | $65.44M | $199.9M | $171.2M | $169.82M | $71.31M | |
| -$47.63M | -$46.15M | -$65.44M | -$199.9M | -$171.2M | -$169.82M | -$71.31M | |
| — | — | — | — | — | — | -43217.58% | |
| — | — | -$65.04M | -$199.5M | -$170.48M | -$169.63M | -$71.24M | |
| $0 | $1.44M | — | — | — | — | — | |
| — | — | $5.49M | $5.73M | $1.88M | $1.32M | $1.33M | |
| $3.53M | $2.71M | $1.19M | $3.62M | $351K | -$2.45M | $195K | |
| — | -$43.44M | -$58.77M | -$190.54M | -$168.98M | -$170.96M | -$69.78M | |
| — | $0 | $0 | -$126K | -$265K | $1.01M | — | |
| -$44.1M | -$43.44M | -$58.77M | -$190.42M | -$168.71M | -$171.96M | -$69.78M | |
| — | — | — | — | — | — | -42293.33% | |
| — | -$43.43M | -$58.84M | -$190.01M | -$169.02M | -$172.01M | -$69.96M | |
| USD/shares | — | -$2.85 | -$11.73 | -$42.09 | -$50.60 | — | — |
| USD/shares | — | -$2.85 | -$11.73 | -$42.09 | -$50.60 | — | — |
| shares | — | 15.27M | 5.01M | 4.52M | 3.33M | 2.73M | 1.17M |
| shares | — | 15.27M | 5.01M | 4.52M | 3.33M | 2.73M | 1.17M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.